These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31226165)

  • 1. Reaching at-risk women for PrEP delivery: What can we learn from clinical trials in sub-Saharan Africa?
    Stankevitz K; Schwartz K; Hoke T; Li Y; Lanham M; Mahaka I; Mullick S
    PLoS One; 2019; 14(6):e0218556. PubMed ID: 31226165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study.
    Mack N; Evens EM; Tolley EE; Brelsford K; Mackenzie C; Milford C; Smit JA; Kimani J
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19157. PubMed ID: 25224616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.
    van der Straten A; Stadler J; Luecke E; Laborde N; Hartmann M; Montgomery ET;
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19146. PubMed ID: 25224610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strengthening health system's capacity for pre-exposure prophylaxis for adolescent girls and young women and adolescent boys and young men in South Africa (SHeS'Cap-PrEP): Protocol for a mixed methods study in KwaZulu-Natal, South Africa.
    Nicol E; Ramraj T; Hlongwa M; Basera W; Jama N; Lombard C; McClinton-Appollis T; Govindasamy D; Pass D; Funani N; Aheron S; Paredes-Vincent A; Drummond J; Cheyip M; Dladla S; Bedford J; Mathews C
    PLoS One; 2022; 17(3):e0264808. PubMed ID: 35298487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
    Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM
    AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preexposure prophylaxis revolution; from clinical trials to programmatic implementation.
    Mugo NR; Ngure K; Kiragu M; Irungu E; Kilonzo N
    Curr Opin HIV AIDS; 2016 Jan; 11(1):80-6. PubMed ID: 26575147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake of and adherence to oral pre-exposure prophylaxis among adolescent girls and young women at high risk of HIV-infection in Kampala, Uganda: A qualitative study of experiences, facilitators and barriers.
    Kayesu I; Mayanja Y; Nakirijja C; Machira YW; Price M; Seeley J; Siu G
    BMC Womens Health; 2022 Nov; 22(1):440. PubMed ID: 36357920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
    Grant H; Gomez GB; Kripke K; Barnabas RV; Watts C; Medley GF; Mukandavire Z
    Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Women and ARV-based HIV prevention - challenges and opportunities.
    Geary CW; Bukusi EA
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19356. PubMed ID: 25224621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
    Murewanhema G; Malisheni M; Takah NF
    Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa.
    McGillen JB; Anderson SJ; Hallett TB
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21104. PubMed ID: 27760682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rethinking HIV prevention to prepare for oral PrEP implementation for young African women.
    Celum CL; Delany-Moretlwe S; McConnell M; van Rooyen H; Bekker LG; Kurth A; Bukusi E; Desmond C; Morton J; Baeten JM
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20227. PubMed ID: 26198350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical exigencies, psychosocial realities: negotiating HIV pre-exposure prophylaxis beyond the cascade among gay, bisexual and other men who have sex with men in Canada.
    Newman PA; Guta A; Lacombe-Duncan A; Tepjan S
    J Int AIDS Soc; 2018 Nov; 21(11):e25211. PubMed ID: 30474351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.
    Celum CL; Delany-Moretlwe S; Baeten JM; van der Straten A; Hosek S; Bukusi EA; McConnell M; Barnabas RV; Bekker LG
    J Int AIDS Soc; 2019 Jul; 22 Suppl 4(Suppl Suppl 4):e25298. PubMed ID: 31328444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
    Bhavaraju N; Shears K; Schwartz K; Mullick S; Jeckonia P; Murungu J; Persaud U; Vij A; Torjesen K
    Curr HIV/AIDS Rep; 2021 Dec; 18(6):508-517. PubMed ID: 34910276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study.
    van der Straten A; Ryan JH; Reddy K; Etima J; Taulo F; Mutero P; Taylor J; Piper J; Musara P;
    J Int AIDS Soc; 2020 Jun; 23(6):e25536. PubMed ID: 32524700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
    Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
    Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision.
    Mudimu E; Peebles K; Mukandavire Z; Nightingale E; Sharma M; Medley GF; Klein DJ; Kripke K; Bershteyn A
    PLoS One; 2020; 15(12):e0244761. PubMed ID: 33382803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study.
    Poteat T; Malik M; van der Merwe LLA; Cloete A; Adams D; Nonyane BAS; Wirtz AL
    Lancet HIV; 2020 Dec; 7(12):e825-e834. PubMed ID: 32622370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.